Ad
related to: Target and Novartis
Search results
Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial
Clinical Trials Arena via Yahoo Finance· 7 hours agoNovartis Cardiovascular, Renal and Metabolism Development Unit global head David Soergel said...IgAN...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
WROC Rochester· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WJET - WFXP Erie· 2 days ago...5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent...
Boston Partners Buys 1,836 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 1 week agoBoston Partners boosted its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 6.1% in the fourth quarter, according to the company in its most recent Form 13F ...
Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal
FierceBiotech· 6 days agoEli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to...
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a...
NBC San Diego· 4 days agoTargeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation...
PNC Financial Services Group Inc. Sells 50,653 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 6 days agoPNC Financial Services Group Inc. decreased its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 17.1% in the fourth quarter, according to its most recent 13F ...
A corner of the cancer therapy market is heating up—Here are the names investors need to know
CNBC· 4 days agoThere's been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 hours agoAcne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma ...
Brown Advisory Inc. Sells 39,471 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 1 week agoBrown Advisory Inc. cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 13.7% during the fourth quarter, according to the company in its most recent 13F filing with ...
